Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peak Surgical closes $21 million Series C financing
Existing investors Lehman Brothers and Venrock Associates also participated in this financing round. John Tighe, president and CEO of Peak Surgical, said: “The size, valuation and timing of
Existing investors Lehman Brothers and Venrock Associates also participated in this financing round. John Tighe, president and CEO of Peak Surgical, said: “The size, valuation and timing of
Centocor has submitted the BLA for ustekinumab (CNTO 1275) in December 2007 based on its development program including data from two large phase III multicenter, randomized, double-blind, placebo-controlled
Acorda also acquired Neurorecovery’s preclinical and clinical data, regulatory filings, copyrights, trademarks and domain names relating to the three products. Two Phase II studies of the aminopyridine compound
The company said that the first patient enrolled in this study responded very favorably to veltuzumab. Prior to receiving a single dose of 80mg of veltuzumab, the patient
The agreement provides Aesculap with the right to sell in the US and includes minimum purchase requirements and the payment of a royalty on sales of disposables. Michael
The company said that the motavizumab biologics license application (BLA) is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention
CV Therapeutics has received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology. Louis
Eyeonics now operates as a wholly-owned subsidiary of Bausch & Lomb. Its crystalens intraocular lens (IOL), the first and only FDA-approved accommodating IOL for the treatment of cataracts,
The approval gives US cardiologists access to a new medical device for safely and effectively treating patients with narrowed coronary arteries. Clinical research has shown that Endeavor provides
Under the terms of the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. The research collaboration focuses on the structural properties of